Allogene Therapeutics (ALLO) News Today $1.45 -0.01 (-0.68%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$1.45 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALLO Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Zacks Research Issues Optimistic Estimate for ALLO EarningsJune 8, 2025 | americanbankingnews.comZacks Research Issues Optimistic Forecast for ALLO EarningsAllogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Equities research analysts at Zacks Research upped their Q2 2025 EPS estimates for shares of Allogene Therapeutics in a note issued to investors on Tuesday, June 3rd. Zacks Research analyst R. Department now forecasts that the company willJune 6, 2025 | marketbeat.comResearch Analysts Issue Forecasts for ALLO Q2 EarningsJune 6, 2025 | americanbankingnews.comHC Wainwright Issues Optimistic Forecast for ALLO EarningsAllogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Research analysts at HC Wainwright raised their Q2 2025 EPS estimates for Allogene Therapeutics in a report issued on Monday, June 2nd. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.26) per share fJune 4, 2025 | marketbeat.comResearch Analysts Set Expectations for ALLO Q1 EarningsJune 4, 2025 | americanbankingnews.comQ1 Earnings Forecast for ALLO Issued By HC WainwrightAllogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Allogene Therapeutics in a report issued on Monday, June 2nd. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($0.27) per sJune 3, 2025 | marketbeat.comAllogene Therapeutics Presents Promising Phase 1 Data for ALLO-316 in Renal Cell CarcinomaJune 2, 2025 | msn.comBank of America Corp DE Buys 579,818 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)Bank of America Corp DE raised its stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 99.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,163,743 shares of the company's stock after purcJune 2, 2025 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Sold by Jane Street Group LLCJane Street Group LLC decreased its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 63.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 164,523 shares of the company's stock after selling 286,198 sharesJune 2, 2025 | marketbeat.comAllogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCOJune 1, 2025 | globenewswire.comAllogene Therapeutics: Buying Around A Potential ASCO Lazarus MomentMay 29, 2025 | seekingalpha.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) have received an average recommendation of "Moderate Buy" from the ten brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating and nine have given a buy ratiMay 29, 2025 | marketbeat.comAllogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade)May 28, 2025 | seekingalpha.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Purchased by Two Sigma Advisers LPTwo Sigma Advisers LP boosted its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 12.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,702,200 shares of the company's sMay 27, 2025 | marketbeat.comAllogene shares update on CAR T-cell therapies at ASCO meetingMay 24, 2025 | investing.comAllogene Therapeutics Announces Participation in Upcoming Investor ConferencesMay 23, 2025 | globenewswire.comAllogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-CelMay 22, 2025 | globenewswire.comUndervalued Opportunities: 3 Penny Stocks With Market Caps Above $30MMay 22, 2025 | finance.yahoo.comBNP Paribas Financial Markets Boosts Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)BNP Paribas Financial Markets lifted its stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 1,732.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 849,658 shares of the company's stock after puMay 20, 2025 | marketbeat.comResearch Analysts Set Expectations for ALLO Q2 EarningsAllogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Research analysts at William Blair boosted their Q2 2025 earnings estimates for Allogene Therapeutics in a research report issued on Wednesday, May 14th. William Blair analyst S. Corwin now expects that the company will post earnings per sMay 20, 2025 | marketbeat.comRaiffeisen Bank International AG Invests $903,000 in Allogene Therapeutics, Inc. (NASDAQ:ALLO)Raiffeisen Bank International AG purchased a new position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 430,000 sharMay 19, 2025 | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) Stock Rating Lowered by Citizens JmpCitizens Jmp downgraded shares of Allogene Therapeutics from an "outperform" rating to a "market perform" rating in a report on Wednesday.May 16, 2025 | marketbeat.comRobert W. Baird Issues Pessimistic Forecast for Allogene Therapeutics (NASDAQ:ALLO) Stock PriceRobert W. Baird lowered their price objective on shares of Allogene Therapeutics from $12.00 to $9.00 and set an "outperform" rating for the company in a research note on Wednesday.May 16, 2025 | marketbeat.comPatient Square Capital LP Makes New $3.17 Million Investment in Allogene Therapeutics, Inc. (NASDAQ:ALLO)Patient Square Capital LP bought a new stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 1,489,909 shares of the company's stock, valued at approxiMay 16, 2025 | marketbeat.comAllogene Therapeutics falls after trial delay, rating downgrade post Q1 resultsMay 15, 2025 | msn.comAllogene extends cash runway into 2027 while prioritizing ALPHA3 and clinical momentumMay 14, 2025 | msn.comAllogene Therapeutics Reports First Quarter 2025 Financial Results and Business UpdateMay 14, 2025 | finance.yahoo.comAllogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comAllogene Therapeutics Reports First Quarter 2025 Financial Results and Business UpdateMay 13, 2025 | globenewswire.comDimensional Fund Advisors LP Raises Stock Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)Dimensional Fund Advisors LP lifted its stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 30.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,561,626 shares of the company's stock after buyingMay 13, 2025 | marketbeat.com6ALLO : Allogene Therapeutics's Earnings OutlookMay 12, 2025 | benzinga.comIs Allogene Therapeutics, Inc. (ALLO) the Low Risk High Reward Stock Set to Triple by 2030?May 9, 2025 | uk.finance.yahoo.com10 Low Risk High Reward Stocks Set to Triple by 2030May 9, 2025 | insidermonkey.comSynnovation Therapeutics Announces the Appointment of Rafael G. Amado, M.D., to Its Board of DirectorsMay 8, 2025 | finance.yahoo.comAllogene Therapeutics Inc.May 7, 2025 | barrons.comAllogene Therapeutics Inc.May 7, 2025 | barrons.comAllogene Therapeutics (ALLO) Projected to Post Earnings on MondayAllogene Therapeutics (NASDAQ:ALLO) will be releasing its Q1 2025 earnings before the market opens on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-allogene-therapeutics-inc-stock/)May 7, 2025 | marketbeat.comAllogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business UpdateMay 6, 2025 | globenewswire.comPrice T Rowe Associates Inc. MD Sells 353,171 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)Price T Rowe Associates Inc. MD reduced its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 7.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 4,485,572 shares of the company's stock after selling 353,171 shares during the qMay 6, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Invests $802,000 in Allogene Therapeutics, Inc. (NASDAQ:ALLO)Susquehanna Fundamental Investments LLC purchased a new position in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 376,661 shares of the company's stock, valueMay 5, 2025 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Consensus Rating of "Moderate Buy" from BrokeragesAllogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and nine have given a buMay 5, 2025 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Bought by Barclays PLCBarclays PLC boosted its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 122.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 761,286 shares of the company's stock after purchasing an additional 418,313 shaMay 5, 2025 | marketbeat.com3,448,275 Shares in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Bought by Foresite Capital Management VI LLCForesite Capital Management VI LLC bought a new position in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 3,448,275 shares of the company's stock, valuedApril 30, 2025 | marketbeat.comLynx1 Capital Management LP Buys 4,672,349 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)Lynx1 Capital Management LP lifted its stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 75.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,874,723 shares of thApril 29, 2025 | marketbeat.comXTX Topco Ltd Buys Shares of 158,537 Allogene Therapeutics, Inc. (NASDAQ:ALLO)XTX Topco Ltd acquired a new position in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 158,537 shares of the company's stock, valued at approximately $338,00April 26, 2025 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) is a favorite amongst institutional investors who own 59%April 25, 2025 | finance.yahoo.comAnnie Yoshiyama Sells 9,601 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) StockApril 24, 2025 | insidertrades.comAllogene Therapeutics to present updated ALLO-316 results at ASCO meetingApril 24, 2025 | markets.businessinsider.comCentury Therapeutics (IPSC) Gets a Hold from William BlairApril 23, 2025 | markets.businessinsider.comAllogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingApril 23, 2025 | globenewswire.com Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLO Media Mentions By Week ALLO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALLO News Sentiment▼1.080.90▲Average Medical News Sentiment ALLO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALLO Articles This Week▼84▲ALLO Articles Average Week Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CALT News Today GPCR News Today AUPH News Today WVE News Today NAGE News Today MLYS News Today RCUS News Today SYRE News Today AKBA News Today CVAC News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALLO) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
